stoxline Quote Chart Rank Option Currency Glossary
  
Collegium Pharmaceutical, Inc. (COLL)
37.13  0.42 (1.14%)    03-01 16:00
Open: 37.14
High: 37.5
Volume: 418,675
  
Pre. Close: 36.71
Low: 36.5
Market Cap: 1,187(M)
Technical analysis
2024-03-01 4:51:35 PM
Short term     
Mid term     
Targets 6-month :  44.13 1-year :  51.55
Resists First :  37.79 Second :  44.13
Pivot price 34.36
Supports First :  33.8 Second :  31.34
MAs MA(5) :  36.75 MA(20) :  34.06
MA(100) :  28.66 MA(250) :  25.25
MACD MACD :  1.1 Signal :  0.7
%K %D K(14,3) :  84.7 D(3) :  83.3
RSI RSI(14): 69.2
52-week High :  37.79 Low :  20.82
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ COLL ] has closed below upper band by 15.1%. Bollinger Bands are 129.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 37.55 - 37.69 37.69 - 37.8
Low: 36.13 - 36.3 36.3 - 36.44
Close: 36.87 - 37.14 37.14 - 37.36
Company Description

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Headline News

Sat, 02 Mar 2024
Collegium Pharmaceutical (NASDAQ:COLL) Downgraded by StockNews.com to “Buy” - AmericanBankingNEWS

Fri, 01 Mar 2024
Are You Looking for a Top Momentum Pick? Why Collegium Pharmaceutical (COLL) is a Great Choice - Zacks Investment Research

Fri, 01 Mar 2024
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Acquired by Trexquant Investment LP - MarketBeat

Thu, 29 Feb 2024
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? - Yahoo Finance

Wed, 28 Feb 2024
Insider Sell: EVP & Chief Commercial Officer Scott Dreyer Sells - GuruFocus.com

Mon, 26 Feb 2024
Collegium Pharmaceutical Inc (COLL) Stock: What Does the Chart Say Monday? - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers—Specialty & Generic
Shares Out 32 (M)
Shares Float 29 (M)
Held by Insiders 1.8 (%)
Held by Institutions 125.3 (%)
Shares Short 6,760 (K)
Shares Short P.Month 6,380 (K)
Stock Financials
EPS 1.28
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.13
Profit Margin 8.5 %
Operating Margin 31.1 %
Return on Assets (ttm) 9.4 %
Return on Equity (ttm) 24.6 %
Qtrly Rev. Growth 15.5 %
Gross Profit (p.s.) 0
Sales Per Share 17.73
EBITDA (p.s.) 10.16
Qtrly Earnings Growth 0 %
Operating Cash Flow 275 (M)
Levered Free Cash Flow 265 (M)
Stock Valuations
PE Ratio 28.78
PEG Ratio 21.7
Price to Book value 6.05
Price to Sales 2.09
Price to Cash Flow 4.31
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android